Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 2/20 | 0.39 |
| ▸ | HTR2B | P41595 | 2/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | CCR1 | P32246 | 1/20 | 0.37 |
| ▸ | CCR5 | P51681 | 1/20 | 0.37 |
| ▸ | CCR8 | P51685 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | APAF1 | O14727 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | TNF | P01375 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | HRH2 | P25021 | 1/20 | 0.34 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL192522 | 0.84 | TSHR (0.42) | LMNASMN1; SMN2TSHRHTR2AHTR2B | |
| SCHEMBL1490884 | 0.83 | TP53 (0.36) | LMNASMN1; SMN2HTTHTR2AHTR2B | |
| SCHEMBL4056414 | 0.81 | ALDH1A1 (0.41) | LMNASMN1; SMN2HTTTSHRALDH1A1 | |
| SCHEMBL6724014 | 0.81 | SMN1; SMN2 (0.47) | LMNASMN1; SMN2HTTTSHRHTR2A | |
| SCHEMBL3355085 | 0.80 | TLR7 (0.45) | KDM4EPDE4DTLR7 | |
| Sotirimod SCHEMBL29395045 | 0.79 | TLR7 (0.50) | LMNAHTR2AHTR2BHTR2CPOLB | |
| Sotirimod SCHEMBL191424 | 0.79 | TLR7 (0.50) | LMNAHTR2AHTR2BHTR2CPOLB | |
| SCHEMBL841480 | 0.78 | ALDH1A1 (0.36) | LMNASMN1; SMN2HTTHTR2AHTR2B | |
| SCHEMBL14000523 | 0.76 | ALDH1A1 (0.33) | LMNASMN1; SMN2HTTTSHRHTR2A | |
| SCHEMBL191733 | 0.76 | HTR2A (0.33) | LMNASMN1; SMN2HTTTSHRHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8436176-B2 | Process for preparing 2-methyl-1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine | MEDICIS PHARMACEUTICAL CORPORATION (US) | 2013-05-07 | — | — | US | claimed |
| EP-1833827-B9 | PROCESS FOR PREPARING 2-METHYL-1-(2-METHYLPROPYL)-1H-IMIDAZO[4,5-C][1,5]NAPHTHYRIDIN-4-AMINE | MEDA AB (SE) | 2012-01-04 | — | — | EP | claimed |
| EP-1833827-B1 | PROCESS FOR PREPARING 2-METHYL-1-(2-METHYLPROPYL)-1H-IMIDAZO[4,5-C][1,5]NAPHTHYRIDIN-4-AMINE | MEDA AB (SE) | 2011-05-25 | — | — | EP | claimed |
| EP-1865957-A4 | METHOD OF TREATING ACTINIC KERATOSIS | MEDA AB (SE) | 2009-05-06 | — | — | EP | claimed |
| US-20080306266-A1 | Process for Preparing 2-Methyl-1-(2-Methylpropyl)-1H-Imidazo[4,5-C][1,5]Naphthyridin-4-Amine | 3M INNOVATIVE PROPERTIES COMPANY | 2008-12-11 | — | — | US | claimed |
| EP-1865957-A2 | METHOD OF TREATING ACTINIC KERATOSIS | Meda AB (SE) | 2007-12-19 | — | — | EP | claimed |
| EP-1833827-A2 | PROCESS FOR PREPARING 2-METHYL-1-(2-METHYLPROPYL)-1H-IMIDAZOÝ4,5-C¨Ý1,5¨NAPHTHYRIDIN-4-AMINE | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2007-09-19 | — | — | EP | claimed |
| WO-2006099275-A2 | METHOD OF TREATING ACTINIC KERATOSIS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2006-09-21 | — | — | WO | claimed |
| WO-2006074046-A2 | PROCESS FOR PREPARING 2-METHYL-1-(2-METHYLPROPYL)-1H-IMIDAZO[4,5-C][1,5]NAPHTHYRIDIN-4-AMINE | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2006-07-13 | — | — | WO | claimed |
| US-8436176-B2 | Process for preparing 2-methyl-1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine | MEDICIS PHARMACEUTICAL CORPORATION (US) | 2013-05-07 | — | — | US | disclosed |
| US-8436176-B2 | Process for preparing 2-methyl-1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine | MEDICIS PHARMACEUTICAL CORPORATION (US) | 2013-05-07 | — | — | US | disclosed |
| EP-1833827-B9 | PROCESS FOR PREPARING 2-METHYL-1-(2-METHYLPROPYL)-1H-IMIDAZO[4,5-C][1,5]NAPHTHYRIDIN-4-AMINE | MEDA AB (SE) | 2012-01-04 | — | — | EP | disclosed |
| EP-1833827-B9 | PROCESS FOR PREPARING 2-METHYL-1-(2-METHYLPROPYL)-1H-IMIDAZO[4,5-C][1,5]NAPHTHYRIDIN-4-AMINE | MEDA AB (SE) | 2012-01-04 | — | — | EP | disclosed |
| EP-1833827-B1 | PROCESS FOR PREPARING 2-METHYL-1-(2-METHYLPROPYL)-1H-IMIDAZO[4,5-C][1,5]NAPHTHYRIDIN-4-AMINE | MEDA AB (SE) | 2011-05-25 | — | — | EP | disclosed |
| US-6514985-B1 | Induce the biosynthesis of cytokines such as interferon and tumor necrosis factor; exhibit antiviral and antitumor properties | 3M INNOVATIVE PROPERTIES COMPANY | 2003-02-04 | — | — | US | disclosed |
| US-20020173653-A1 | Imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY | 2002-11-21 | — | — | US | disclosed |
| US-20020173654-A1 | Imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY | 2002-11-21 | — | — | US | disclosed |
| US-6194425-B1 | VIRICIDES, ANTITUMOR AGENTS | 3M INNOVATIVE PROPERTIES COMPANY | 2001-02-27 | — | — | US | disclosed |
| EP-1040112-A1 | IMIDAZONAPHTHYRIDINES AND THEIR USE IN INDUCING CYTOKINE BIOSYNTHESIS | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 2000-10-04 | — | — | EP | disclosed |
| WO-1999029693-A1 | IMIDAZONAPHTHYRIDINES AND THEIR USE IN INDUCING CYTOKINE BIOSYNTHESIS | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1999-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020173653-A1 | Imidazonaphthyridines | IFNG, IRF3, IFNAR1 | LMNA 3209/4885SMN1; SMN2 4092/4885HTT 3763/4885 |
| US-20020173654-A1 | Imidazonaphthyridines | IFNG, IRF3, IFNAR1 | LMNA 3209/4885SMN1; SMN2 4092/4885HTT 3763/4885 |
| US-20080306266-A1 | Process for Preparing 2-Methyl-1-(2-Methylpropyl)-1H-Imidazo[4,5-C][1,5]Naphthyridin-4-Amine | DNMT1, NT5C, JMJD1C | LMNA 166/4885SMN1; SMN2 448/4885HTT 2585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.